The Research Group of Prof. Roland Eils at the BioQuant Center and the Institute of Pharmacy and Molecular Biotechnology at Heidelberg University is developing computer-assisted methods for interpreting complex genomic data.
We are looking for a
Postdoc / Bioinformatician (m/f)
Our research group is involved in bioinformatic analysis of diverse data sets arising from various international consortia like the International Cancer Genome Consortium (ICGC) and recently the Human Cell Atlas Initiative (Regev et al., bioRxiv, 2017). Within the TRR project, we will extend our expertise to the genomic profiling of hepatitis virus infected patients.
We are seeking a highly motivated postdoctoral researcher to perform integrative analysis on large genomic and epigenomic (including DNA methylation, RNA-seq and ChIP-seq) datasets which are either already available in our group or which will be generated using state-of-the-art sequencing techniques.
· PhD with a substantial component in bioinformatics, computational biology, or computer science (or equivalent experience)
· Good understanding of molecular and cancer biology
· Working experience with UNIX OS, Python, R
· Experience in the analysis of next generation sequencing data is a strong plus
· Excellent oral and written communication skills in English
· Ability to work independently and excellent team working skills
· Organizational skills and ability to supervise students and PhD students
· Highly interesting position in an interdisciplinary setting
· Participation in leading national and international research consortia
· Stimulating international research environment
· Broad expertise in cancer genomics and systems biology with proven track record of high impact publications
· Excellent computational infrastructure including state-of-the-art computer cluster and petabyte-scale data storage facilities
The position is initially limited to two years with possibilities for extension. Salary is according to TV-L. The position can in principle be part-time.
Application deadline: February 15th, 2018